14-Jun-2024
Clover Health gains on recalculated Medicare Star Ratings
Seeking Alpha News (Fri, 14-Jun 10:22 AM ET)
Globe Newswire (Fri, 14-Jun 9:00 AM ET)
Globe Newswire (Wed, 29-May 8:00 AM ET)
Globe Newswire (Tue, 7-May 4:05 PM ET)
Globe Newswire (Wed, 1-May 4:05 PM ET)
Clover Health Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 30-Apr 4:15 PM ET)
Clover Health to Report First Quarter 2024 Financial Results on May 7, 2024
Globe Newswire (Tue, 23-Apr 4:05 PM ET)
Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer
Globe Newswire (Mon, 22-Apr 4:05 PM ET)
Globe Newswire (Thu, 4-Apr 4:30 PM ET)
Globe Newswire (Tue, 19-Mar 9:00 AM ET)
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. Operating in two segments, Insurance and Non-Insurance, Clover Health offers PPO and HMO plans to Medicare Advantage members in multiple states through its Insurance segment. In the Non-Insurance segment, the company participates in the ACO REACH Model. The majority of revenue is generated from the insurance segment, reflecting the significance of its healthcare insurance offerings.
Clover Health Investments Corp. - Class A trades on the NASDAQ stock market under the symbol CLOV.
As of June 14, 2024, CLOV stock price climbed to $1.09 with 4,692,703 million shares trading.
CLOV has a beta of 1.82, meaning it tends to be more sensitive to market movements. CLOV has a correlation of 0.13 to the broad based SPY ETF.
CLOV has a market cap of $539.87 million. This is considered a Small Cap stock.
Last quarter Clover Health Investments Corp. - Class A reported $347 million in Revenue and -$.05 earnings per share. This beat revenue expectation by $26 million and exceeded earnings estimates by $.02.
In the last 3 years, CLOV stock traded as high as $15.47 and as low as $.61.
The top ETF exchange traded funds that CLOV belongs to (by Net Assets): VTI, VXF, SCHA, PRFZ, FNDA.
CLOV has underperformed the market in the last year with a price return of +15.8% while the SPY ETF gained +25.7%. However, in the short term, CLOV had mixed performance relative to the market. It has outperformed in the last 3 months, returning +50.3% vs +6.0% return in SPY. But in the last 2 weeks, CLOV shares have been beat by the market, returning -0.9% compared to an SPY return of +2.9%.
CLOV support price is $.98 and resistance is $1.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLOV stock will trade within this expected range on the day.